JP7237962B2 - 自己免疫性微小血管系障害を治療する方法 - Google Patents

自己免疫性微小血管系障害を治療する方法 Download PDF

Info

Publication number
JP7237962B2
JP7237962B2 JP2020524721A JP2020524721A JP7237962B2 JP 7237962 B2 JP7237962 B2 JP 7237962B2 JP 2020524721 A JP2020524721 A JP 2020524721A JP 2020524721 A JP2020524721 A JP 2020524721A JP 7237962 B2 JP7237962 B2 JP 7237962B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
pharmaceutically acceptable
therapeutically effective
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528454A (ja
JP2020528454A5 (https=
Inventor
エム．レビー ロバート
Original Assignee
プライマス ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プライマス ファーマシューティカルズ，インコーポレイティド filed Critical プライマス ファーマシューティカルズ，インコーポレイティド
Publication of JP2020528454A publication Critical patent/JP2020528454A/ja
Publication of JP2020528454A5 publication Critical patent/JP2020528454A5/ja
Application granted granted Critical
Publication of JP7237962B2 publication Critical patent/JP7237962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020524721A 2017-07-19 2018-07-18 自己免疫性微小血管系障害を治療する方法 Active JP7237962B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
US62/534,237 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (3)

Publication Number Publication Date
JP2020528454A JP2020528454A (ja) 2020-09-24
JP2020528454A5 JP2020528454A5 (https=) 2021-07-26
JP7237962B2 true JP7237962B2 (ja) 2023-03-13

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524721A Active JP7237962B2 (ja) 2017-07-19 2018-07-18 自己免疫性微小血管系障害を治療する方法

Country Status (12)

Country Link
US (2) US11278517B2 (https=)
EP (2) EP3654965B1 (https=)
JP (1) JP7237962B2 (https=)
KR (1) KR102717665B1 (https=)
CN (1) CN111065389B (https=)
AU (1) AU2018304208B2 (https=)
CA (1) CA3069921C (https=)
ES (1) ES2957742T3 (https=)
HR (1) HRP20231517T1 (https=)
MX (1) MX2020000625A (https=)
PL (1) PL3654965T3 (https=)
WO (1) WO2019018455A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法
WO2026014965A1 (ko) * 2024-07-11 2026-01-15 한국 한의학 연구원 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153648A1 (en) 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153648A1 (en) 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Alternative Medicine Review，2004年，Vol.9, No.3，pp.308-311
Post Dermatol Alergol，2007年，XXIV, 3，pp.144-149
Reumatol Clin.，2012年，8(5)，pp.270-277

Also Published As

Publication number Publication date
AU2018304208A1 (en) 2020-02-13
US11844777B2 (en) 2023-12-19
PL3654965T3 (pl) 2024-02-26
EP3654965A1 (en) 2020-05-27
CN111065389B (zh) 2023-11-21
KR20200051579A (ko) 2020-05-13
EP4269397A3 (en) 2024-01-31
WO2019018455A1 (en) 2019-01-24
US11278517B2 (en) 2022-03-22
KR102717665B1 (ko) 2024-10-14
ES2957742T3 (es) 2024-01-24
EP3654965A4 (en) 2021-03-10
AU2018304208B2 (en) 2022-03-17
CA3069921A1 (en) 2019-01-24
JP2020528454A (ja) 2020-09-24
EP3654965C0 (en) 2023-09-06
EP3654965B1 (en) 2023-09-06
US20220168267A1 (en) 2022-06-02
HRP20231517T1 (hr) 2024-03-01
CA3069921C (en) 2022-01-18
US20200147031A1 (en) 2020-05-14
EP4269397A2 (en) 2023-11-01
MX2020000625A (es) 2020-09-28
CN111065389A (zh) 2020-04-24

Similar Documents

Publication Publication Date Title
Elia et al. Clonidine as an adjuvant to intrathecal local anesthetics for surgery: systematic review of randomized trials
US6444681B1 (en) Methods and compositions for treating Raynaud's Phenomenon and scleroderma
WO2011127586A1 (en) Topical treatments for pain
CN102655861A (zh) 用于治疗放疗或化疗引起的粘膜炎的组合
JP7237962B2 (ja) 自己免疫性微小血管系障害を治療する方法
HU228989B1 (en) Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
RU2008148597A (ru) Фармацевтические комбинации
Kang The effect of dexmedetomidine added to preemptive ropivacaine infiltration on post-operative pain after inguinal herniorrhaphy: a prospective, randomized, double-blind, placebo-controlled study
JP2016094450A (ja) 薬物誘発性手足症候群を治療するための組成物および方法
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
JP5727642B2 (ja) センタキンを用いた新規の治療方法
MX2007003948A (es) Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
Cheung et al. A double-blind randomized crossover study to evaluate the timing of pregabalin for third molar surgery under local anesthesia
Herrmann et al. Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac
RU2010144795A (ru) Применение комбинации уденафила и алфузозина или оксибутинина для лечения гиперактивного мочевого пузыря
NO326446B1 (no) Anvendelse av deoksypeganin, som fri base eller som et syreaddisjonssalt, for fremstilling av et medikament til behandling av klinisk depresjon
AU2012244095A1 (en) Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual
Kale et al. Controlled comparative trial of thiabendazole and metronidazole in the treatment of dracontiasis
RU2329810C1 (ru) Способ лечения больных язвенной болезнью
EP4387621A1 (en) Use of a new therapeutic combination to treat chronic venous insufficiency
Mohamed et al. Transdermal nitroglycerine as a coadjuvant to intrathecal nalbuphine with bupivacaine in lower abdominal surgery.
WO2025264860A3 (en) Methods of treating post-covid airway disease
Kumar et al. Efficacy of postoperative antibiotics after appendectomy in patients with non perforated appendicitis-A Clinical Study
JP2011528345A (ja) 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用
Halaszynski Management of Oral Ulcers and Burning Mouth Syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230301

R150 Certificate of patent or registration of utility model

Ref document number: 7237962

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250